As preparation for entering into the clinical stage of its lead NexVas™ ApoA-I technology program Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that Dr. Gregory S. Wagner has joined the company as Vice President of Preclinical Development. Dr. Wagner will help lead the company's efforts in developing its cardiovascular programs NexVas™ and ReVas™ towards IND (Investigational New Drug) submission to FDA (Food and Drug administration).
